The World Health Organization (WHO) Vaccine Safety Commission states in its latest guidance that the benefits of the Messenger RNA COVID-19 vaccine outweigh the risks of heart inflammation.
After reviewing all currently available information, the WHO Global Advisory Board on Vaccine Safety (GACVS), despite evidence suggesting a possible link between cardiac inflammation and emergency use mRNA vaccines. Announcement On July 9, the benefits of the vaccine were found to continue to outweigh the risks of myocarditis and pericarditis to individuals.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the inner layer surrounding the heart. The inflammatory condition can occur after administration of the mRNA vaccine or as a result of infection with the CCP (Chinese Communist Party) virus that causes COVID-19 disease.
This guidance is the same as the US Centers for Disease Control and Prevention (CDC) guidelines for cardiac inflammation after vaccination of people over the age of 12 with the mRNA vaccine. WHO does not distinguish guidance by age.
Last month, the CDC’s Vaccine Advisory Board said it would not change its vaccine recommendations for “people over the age of 12 in the United States under the FDA’s Emergency Use Authorization” after discussing the high incidence of heart inflammation in young people. It was. Especially among men aged 12 to 24 years.
The Commission concluded that the risk of cardiac inflammation in adolescents and young adults after mRNA vaccination did not outweigh the benefits of the vaccine and only recommended disclosing the risk of cardiac inflammation to patients.
GACVS also claimed that cases of cardiac inflammation after mRNA vaccination were very rare, generally mild, and usually improved with treatments such as non-steroidal anti-inflammatory drugs and rest.
However, more than expected reports of heart inflammation in adolescents and young adults, especially young men, usually require further investigation of this issue by health authorities in various countries within a few days after the second dose of the mRNA vaccine. I urged you.
The European Medicines Agency (EMA) Safety Commission met last week to discuss 321 cases of myocarditis and pericarditis reported after mRNA vaccination. As of May 31, 2021, the European Economic Area has received approximately 197 million doses of mRNA vaccine.
He concluded that cardiac inflammation “can occur in very rare cases” and “listed myocarditis and pericarditis as new side effects in the product information for these vaccines, with medical professionals and these vaccines. It warns people who are taking the drug to raise their awareness. “
“The Commission concluded that the cases occurred primarily within 14 days after vaccination and in younger adult males after the second dose,” said EMA. Said..
Of the 321 cases of myocarditis or pericarditis, 5 of the “elderly or comorbidities” died.
“Medical professionals need to pay attention to the signs and symptoms of myocarditis and pericarditis,” said European drug regulators, experiencing chest pain, shortness of breath, and “potentially irregular strong heartbeats.” If you do, you should see a doctor immediately. After receiving the mRNA vaccine.
Pfizer and Moderna did not respond to requests for comment.